公开(公告)号：US20240277717A1

公开(公告)日：2024-08-22

申请号：US18358958

申请日：2023-07-26

申请人： Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

发明人： Jianjun Chen

IPC分类号： A61K31/522 ,  A61K45/06 ,  A61P37/08

CPC分类号： A61K31/522 ,  A61K45/06 ,  A61P37/08

摘要： Ganciclovir (GCV) is a heterocyclic compound containing a purine ring. An application of the GCV in preparation of a medicine for treating allergic rhinitis is provided, in which the GCV is used as an only active component or use the GCV in combination with another medicine. Studies have shown that the GCV can effectively ameliorate symptoms of AR (allergic rhinitis) patients who are ineffective to anti-allergic medicine treatment in clinical and improve their quality of life. It is found from transcriptomics that the GCV regulates the function of nasal mucosal cilium cells, goblet cells and leukocytes. It is also found that the GCV may change immune balance of body by increasing regulatory T cells, thereby alleviating allergic symptoms in vitro peripheral blood mononuclear cells (PBMCs) medicine test.

公开(公告)号：US12064435B2

公开(公告)日：2024-08-20

申请号：US17744339

申请日：2022-05-13

申请人： ONCOCROSS CO., LTD.

发明人： Yi-Rang Kim ,  Jin-Woo Choi

IPC分类号： A61K31/522 ,  A23L33/10 ,  A61K31/197 ,  A61K31/437 ,  A61K45/06 ,  A61P21/00 ,  A61P21/04

CPC分类号： A61K31/522 ,  A61K31/197 ,  A61K31/437 ,  A61K45/06

摘要： The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.

公开(公告)号：US20240261291A1

公开(公告)日：2024-08-08

申请号：US18567653

申请日：2022-06-10

申请人： Brien Holden Vision Institute Limited

发明人： Padmaja Rajagopal Sankaridurg

IPC分类号： A61K31/522 ,  A61K9/00 ,  A61K45/06 ,  A61P27/10

CPC分类号： A61K31/522 ,  A61K9/0048 ,  A61K45/06 ,  A61P27/10

摘要： An ophthalmic composition comprising: an adenosine receptor antagonist (e.g., caffeine or a related compound) or a combination of an adenosine receptor antagonist (e.g., caffeine or a related compound) and one or more parasympathomimetics and/or muscarinic receptor agonists, and methods of using the same.

公开(公告)号：US12053475B2

公开(公告)日：2024-08-06

申请号：US17451148

申请日：2021-10-15

申请人： UNIVERSITY OF LEEDS

发明人： David John Beech ,  Richard James Foster ,  Sin Ying Cheung ,  Baptiste Michel Rode

IPC分类号： A61K31/522 ,  A61K31/4184 ,  A61K31/713 ,  A61P3/04 ,  A61P3/10

CPC分类号： A61K31/522 ,  A61K31/4184 ,  A61K31/713 ,  A61P3/04 ,  A61P3/10

摘要： Described herein are inhibitors Transient Receptor Potential Canonical (TRPC) ion channels comprising TRPC4 protein and/or TRPC5 protein for use in combating obesity and other medical conditions including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.

公开(公告)号：US20240238478A1

公开(公告)日：2024-07-18

申请号：US18425208

申请日：2024-01-29

申请人： THE SECANT GROUP, LLC

发明人： Stephanie Reed ,  Carissa Smoot ,  Dennis Shull ,  Todd Crumbling ,  John D'Ottavio ,  Peter D. Gabriele ,  Jeremy J. Harris ,  Charles Brendan Nicholson ,  Jared Ely

IPC分类号： A61L27/18 ,  A61K31/522 ,  A61L27/54 ,  B29C64/10 ,  B29C67/24 ,  B33Y10/00 ,  B33Y80/00

CPC分类号： A61L27/18 ,  A61K31/522 ,  A61L27/54 ,  B29C67/246 ,  B33Y80/00 ,  B29C64/10 ,  B33Y10/00

摘要： A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

公开(公告)号：US12036237B2

公开(公告)日：2024-07-16

申请号：US18303694

申请日：2023-04-20

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  INRA, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE ,  CNRS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE STRASBOURG

发明人： Sébastien Roux ,  Thierry Plouvier ,  Julie Le Merrer ,  Jérôme Becker

IPC分类号： A61K33/00 ,  A61K31/522 ,  A61P25/00

CPC分类号： A61K33/00 ,  A61K31/522 ,  A61P25/00

摘要： The present invention relates to a novel pharmaceutical use of bromide, i.e. the treatment of autism spectral disorder (ASD).

公开(公告)号：US20240216382A1

公开(公告)日：2024-07-04

申请号：US18606678

申请日：2024-03-15

申请人： PHARMATHEN S.A.

发明人： EVANGELOS KARAVAS ,  EFTHYMIOS KOUTRIS ,  VASILIKI SAMARA ,  IOANNA KOUTRI ,  ANASTASIA KALASKANI ,  LIDA KALANTZI ,  ANDREAS KAKOURIS ,  AMALIA DIAKIDOU ,  GEORGE GOTZAMANIS ,  ZAHARIAS GEORGOUSIS ,  MANOLIS FOUSTERIS

IPC分类号： A61K31/522 ,  A61K9/00 ,  A61K9/14 ,  A61K9/16

CPC分类号： A61K31/522 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/141 ,  A61K9/145 ,  A61K9/1629 ,  A61K9/1652

摘要： A powder including Valaciclovir or pharmaceutical acceptable salt or derivative thereof and an ion exchange resin. The Valaciclovir is in complex with the ion exchange resin forming Drug-Resin complex (DRC) particles, and each DRC particle comprises hydrogen bonds between the ion exchange resin and a cationic center of Valaciclovir. The ratio of Valaciclovir to the ion exchange resin in the DRC particle is 1:0.5. The powder further includes a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. The powder is configured to be reconstituted with an aqueous diluent as suspension for oral administration.

公开(公告)号：US20240207408A1

公开(公告)日：2024-06-27

申请号：US18595716

申请日：2024-03-05

申请人： Infirst Healthcare Limited

发明人： Robin M. Bannister ,  John Brew ,  Richard R. Reiley, III ,  WILSON CAPARROS WANDERLEY

IPC分类号： A61K47/14 ,  A61K9/08 ,  A61K31/121 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/222 ,  A61K31/357 ,  A61K31/366 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/522 ,  A61K31/60 ,  A61K31/616 ,  A61K47/10 ,  A61K47/22 ,  A61K47/44

CPC分类号： A61K47/14 ,  A61K31/121 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/222 ,  A61K31/357 ,  A61K31/366 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/522 ,  A61K31/60 ,  A61K31/616 ,  A61K47/10 ,  A61K47/22 ,  A61K9/08 ,  A61K47/44 ,  Y02A50/30

摘要： The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions.

公开(公告)号：US20240189236A1

公开(公告)日：2024-06-13

申请号：US18577357

申请日：2022-07-07

申请人： Evonik Operations GmbH

发明人： Erna ROTH ,  Andrea ENGEL ,  Peter NIEPOTH ,  Lisa GÜTTLER ,  Andreas KLOSENDORF

IPC分类号： A61K9/16 ,  A61K8/02 ,  A61K31/522

CPC分类号： A61K9/1635 ,  A61K8/0254 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/1682 ,  A61K31/522 ,  A61K2800/10 ,  A61K2800/41 ,  A61K2800/624

摘要： A composition suitable as coating or binding agent for pharmaceutically, nutraceutically or cosmetically active ingredients includes:



a) at least one (meth)acrylate copolymer a), including polymerized units of 5-25% by weight of methacrylic acid and 75-95% by weight of C1-4-alkylesters of methacrylic acid and/or C1-4-alkylesters of acrylic acid, and
b) 1-25% by weight, based on the total weight of at least one (meth)acrylate copolymer a), of an alkali or ammonium salt of a saturated aliphatic monocarboxylic acid having 10 to 30 carbon atoms,
and c) or d) or both c) and d)
c) 2-25% by weight, based on the total weight of a), of at least one compound selected from glyceryl tristearate, hydroxypropyl methylcellulose, glyceryl behenate, and glyceryl monostearate and/or
d) 25-90% by weight, based on the total weight of a), of at least one selected from talc, rice hulls in powder form, magnesium stearate, corn starch, and microcrystalline cellulose.

公开(公告)号：US11992477B2

公开(公告)日：2024-05-28

申请号：US17058883

申请日：2019-05-28

申请人： HUA Medicine (Shanghai) Ltd.

发明人： Li Chen ,  Yongguo Li ,  Gaosen Wang ,  Huisheng Gao

IPC分类号： A61K31/4155 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K31/155 ,  A61K31/40 ,  A61K31/403 ,  A61K31/4035 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/522 ,  A61K31/7034 ,  A61K45/06 ,  A61K47/38 ,  A61P3/10 ,  C07D231/38 ,  C07D403/12

CPC分类号： A61K31/4155 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1694 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/2095 ,  A61K9/2813 ,  A61K9/284 ,  A61K9/2866 ,  A61K31/155 ,  A61K31/40 ,  A61K31/403 ,  A61K31/4035 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/522 ,  A61K31/7034 ,  A61K45/06 ,  A61K47/38 ,  A61P3/10 ,  C07D231/38 ,  C07D403/12

摘要： The present invention relates to a pharmaceutical combination, comprising a glucokinase activator or a pharmaceutically acceptable salt, isotopic label, crystal form, hydrate, solvate, diastereomer, or enantiomer thereof and an SGLT-2 inhibitor. The present invention further relates to a pharmaceutical composition, a fixed-dose combination preparation, and preparation methods and uses thereof.